Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.42 |
| ▸ | ITGAV | P06756 | 8/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424193 | 0.69 | ITGB3 (0.59) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL5879963 | 0.64 | ITGB3 (0.90) | ITGB3ITGAV | |
| SCHEMBL5026370 | 0.63 | ITGB3 (0.63) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL18381352 | 0.63 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB5LMNA | |
| SCHEMBL10401970 | 0.63 | CYP1A2 (0.53) | ITGB3ITGAVALDH1A1 | |
| SCHEMBL6439458 | 0.63 | ITGB3 (0.49) | ITGB3ITGAVLMNA | |
| SCHEMBL8145501 | 0.62 | CYP1A2 (0.56) | ITGB3ITGAVALOX15ALDH1A1 | |
| SCHEMBL6301697 | 0.61 | ITGB3 (0.52) | ITGB3ITGAVITGA2BDPP4ITGB5 | |
| SCHEMBL5879535 | 0.61 | ITGB3 (0.75) | ITGB3ITGAVKDM4E | |
| SCHEMBL8180590 | 0.61 | ITGB3 (0.62) | ITGB3ITGAVITGA2BITGB5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885ITGA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.